These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 30908864)

  • 21. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
    Xiong Y; Wang Y; Tiruthani K
    Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering nanoparticle strategies for effective cancer immunotherapy.
    Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
    Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.
    Duan X; Chan C; Lin W
    Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy.
    Gao J; Wang WQ; Pei Q; Lord MS; Yu HJ
    Acta Pharmacol Sin; 2020 Jul; 41(7):986-994. PubMed ID: 32317755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy.
    Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO
    Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle-based immunotherapy for cancer.
    Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
    ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and nanoengineering approaches towards activatable cancer immunotherapy.
    Zhang C; Pu K
    Chem Soc Rev; 2020 Jul; 49(13):4234-4253. PubMed ID: 32452475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanoparticles: Properties and Applications in Cancer Immunotherapy.
    Iscaro A; Howard NF; Muthana M
    Curr Pharm Des; 2019; 25(17):1962-1979. PubMed ID: 31566122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Engineering Cells for Cancer Immunotherapy.
    Xu X; Li T; Shen S; Wang J; Abdou P; Gu Z; Mo R
    Theranostics; 2019; 9(25):7889-7905. PubMed ID: 31695806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.
    Li Y; Ayala-Orozco C; Rauta PR; Krishnan S
    Nanoscale; 2019 Oct; 11(37):17157-17178. PubMed ID: 31531445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.
    Fan Y; Moon JJ
    Vaccines (Basel); 2015 Aug; 3(3):662-85. PubMed ID: 26350600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer immunotherapy from biology to nanomedicine.
    Abdelbaky SB; Ibrahim MT; Samy H; Mohamed M; Mohamed H; Mustafa M; Abdelaziz MM; Forrest ML; Khalil IA
    J Control Release; 2021 Aug; 336():410-432. PubMed ID: 34171445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy.
    Han S; Huang K; Gu Z; Wu J
    Nanoscale; 2020 Jan; 12(2):413-436. PubMed ID: 31829394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy.
    Yang Y; Huang J; Liu M; Qiu Y; Chen Q; Zhao T; Xiao Z; Yang Y; Jiang Y; Huang Q; Ai K
    Adv Sci (Weinh); 2023 Jan; 10(2):e2204365. PubMed ID: 36437106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
    Mougel A; Terme M; Tanchot C
    Front Immunol; 2019; 10():467. PubMed ID: 30923527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved cancer immunotherapy strategies by nanomedicine.
    Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.
    Rawding PA; Bu J; Wang J; Kim DW; Drelich AJ; Kim Y; Hong S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1752. PubMed ID: 34414690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology in the arena of cancer immunotherapy.
    Asadujjaman M; Cho KH; Jang DJ; Kim JE; Jee JP
    Arch Pharm Res; 2020 Jan; 43(1):58-79. PubMed ID: 31956965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.